TherapeuticsMD
Market Cap
US$293.2m
Last Updated
2020/03/30 04:14 UTC
Data Sources
Company Financials +
Executive Summary
TherapeuticsMD, Inc. operates as a women’s healthcare company in the United States.
Rewards
Risk Analysis
Snowflake Analysis
High growth potential with mediocre balance sheet.
Similar Companies
Share Price & News
How has TherapeuticsMD's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: TXMD's share price has been volatile over the past 3 months.
Market Performance
7 Day Return
10.8%
TXMD
9.9%
US Pharmaceuticals
12.5%
US Market
1 Year Return
-77.6%
TXMD
-12.4%
US Pharmaceuticals
-12.7%
US Market
Return vs Industry: TXMD underperformed the US Pharmaceuticals industry which returned -12.4% over the past year.
Return vs Market: TXMD underperformed the US Market which returned -12.7% over the past year.
Shareholder returns
| TXMD | Industry | Market | |
|---|---|---|---|
| 7 Day | 10.8% | 9.9% | 12.5% |
| 30 Day | -36.1% | -8.4% | -14.7% |
| 90 Day | -55.4% | -16.9% | -21.5% |
| 1 Year | -77.6%-77.6% | -10.1%-12.4% | -10.9%-12.7% |
| 3 Year | -85.4%-85.4% | 6.7%-1.0% | 12.6%5.4% |
| 5 Year | -82.8%-82.8% | 10.5%-1.7% | 31.9%17.5% |
Price Volatility Vs. Market
How volatile is TherapeuticsMD's share price compared to the market and industry in the last 5 years?
Simply Wall St News
2 weeks ago | Simply Wall St
Some TherapeuticsMD (NASDAQ:TXMD) Shareholders Have Taken A Painful 78% Share Price Drop1 month ago | Simply Wall St
TherapeuticsMD, Inc. Yearly Results: Here's What Analysts Are Forecasting For Next Year1 month ago | Simply Wall St
Before You Buy TherapeuticsMD, Inc. (NASDAQ:TXMD), Consider Its VolatilityValuation
Is TherapeuticsMD undervalued compared to its fair value and its price relative to the market?
>50%
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: TXMD ($1.08) is trading below our estimate of fair value ($14.85)
Significantly Below Fair Value: TXMD is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: TXMD is unprofitable, so we can't compare its PE Ratio to the Pharmaceuticals industry average.
PE vs Market: TXMD is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate TXMD's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: TXMD is overvalued based on its PB Ratio (31.8x) compared to the US Pharmaceuticals industry average (2.4x).
Next Steps
Future Growth
How is TherapeuticsMD forecast to perform in the next 1 to 3 years based on estimates from 8 analysts?
62.4%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: TXMD is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1.7%).
Earnings vs Market: TXMD is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: TXMD's is expected to become profitable in the next 3 years.
Revenue vs Market: TXMD's revenue (37.6% per year) is forecast to grow faster than the US market (7.3% per year).
High Growth Revenue: TXMD's revenue (37.6% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if TXMD's Return on Equity is forecast to be high in 3 years time
Next Steps
Past Performance
How has TherapeuticsMD performed over the past 5 years?
-19.0%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: TXMD is currently unprofitable.
Growing Profit Margin: TXMD is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: TXMD is unprofitable, and losses have increased over the past 5 years at a rate of -19% per year.
Accelerating Growth: Unable to compare TXMD's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: TXMD is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-0.2%).
Return on Equity
High ROE: TXMD has a negative Return on Equity (-1914.39%), as it is currently unprofitable.
Next Steps
Financial Health
How is TherapeuticsMD's financial position?
Financial Position Analysis
Short Term Liabilities: TXMD's short term assets ($208.4M) exceed its short term liabilities ($53.0M).
Long Term Liabilities: TXMD's short term assets ($208.4M) exceed its long term liabilities ($203.8M).
Debt to Equity History and Analysis
Debt Level: TXMD's debt to equity ratio (2115.3%) is considered high.
Reducing Debt: Insufficient data to determine if TXMD's debt to equity ratio has reduced over the past 5 years.
Balance Sheet
Inventory Level: TXMD has a low level of unsold assets or inventory.
Debt Coverage by Assets: TXMD's debt is covered by short term assets (assets are 1.1x debt).
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: TXMD has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: TXMD has sufficient cash runway for 1.2 years if free cash flow continues to reduce at historical rates of -25.4% each year.
Next Steps
Dividend
What is TherapeuticsMD's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate TXMD's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate TXMD's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if TXMD's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if TXMD's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of TXMD's dividend in 3 years as they are not forecast to pay a notable one for the US market.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
7.7yrs
Average management tenure
CEO
Rob Finizio (48yo)
8.42s
Tenure
Mr. Robert G. Finizio, also known as Rob, is the Co-Founder of TherapeuticsMD, Inc. and has been its Chief Executive Officer since October 4, 2011. Mr. Finizio serves as Director of ZyVersa Therapeutics, I ...
CEO Compensation Analysis
Compensation vs Market: Rob's total compensation ($USD0.00) is below average for companies of similar size in the US market ($USD1.49M).
Compensation vs Earnings: Rob's compensation has increased whilst the company is unprofitable.
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 8.42yrs | no data | 7.49% $22.0m | |
| President | 8.42yrs | no data | 2.05% $6.0m | |
| Co-Founder | no data | US$1.21m | 2.45% $7.2m | |
| CFO & Treasurer | 8.42yrs | no data | no data | |
| Executive VP and Chief Strategy & Performance Officer | 8.42yrs | no data | no data | |
| Vice President of Finance | 6.92yrs | no data | no data | |
| Vice President of Commercial Development & Operations | no data | no data | no data | |
| Chief Scientific Officer and Head of Regulatory Department | 6.25yrs | no data | no data | |
| Chief Information Officer | 2yrs | no data | no data | |
| Vice President of Investor Relations | 2.17yrs | no data | no data |
7.7yrs
Average Tenure
52yo
Average Age
Experienced Management: TXMD's management team is seasoned and experienced (7.7 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 8.42yrs | no data | 7.49% $22.0m | |
| Independent Director | no data | no data | no data | |
| Independent Director | no data | no data | no data | |
| Independent Director | 5yrs | US$256.29k | 0.034% $101.0k | |
| Independent Director | 5yrs | US$260.79k | 0.0037% $10.8k | |
| Independent Chairman of the Board | 7.83yrs | US$378.31k | 0.26% $751.1k | |
| Independent Director | 8yrs | US$272.54k | 0.024% $71.3k | |
| Independent Director | 6.83yrs | US$245.04k | 0.0018% $5.4k | |
| Independent Director | 8yrs | US$275.04k | 0.0037% $10.8k | |
| Independent Director | 2yrs | US$247.29k | 0.0012% $3.4k |
7.3yrs
Average Tenure
60.5yo
Average Age
Experienced Board: TXMD's board of directors are considered experienced (7.3 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Ownership Breakdown
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 9.5%.
Top Shareholders
Company Information
TherapeuticsMD, Inc.'s company bio, employee growth, exchange listings and data sources
Key Information
- Name: TherapeuticsMD, Inc.
- Ticker: TXMD
- Exchange: NasdaqGS
- Founded: 2008
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$293.248m
- Shares outstanding: 271.53m
- Website: https://www.therapeuticsmd.com
Number of Employees
Location
- TherapeuticsMD, Inc.
- 951 Yamato Road
- Suite 220
- Boca Raton
- Florida
- 33431
- United States
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| TXMD | NasdaqGS (Nasdaq Global Select) | Yes | Common Stock | US | USD | Oct 2011 |
| 29T | DB (Deutsche Boerse AG) | Yes | Common Stock | DE | EUR | Oct 2011 |
| 29T | BRSE (Berne Stock Exchange) | Yes | Common Stock | CH | CHF | Oct 2011 |
Biography
TherapeuticsMD, Inc. operates as a women’s healthcare company in the United States. The company offers IMVEXXY for the treatment of moderate-to-severe dyspareunia; BIJUVA, a bio-identical hormone therapy combination of 17ß-estradiol and progesterone for the treatment of moderate-to-severe vasomotor symptoms; and ANNOVERA, a ring-shaped contraceptive vaginal system. Its preclinical projects include the development of TX-005HR, a progesterone-alone transdermal cream; TX-006HR, an estradiol and progesterone transdermal cream; and TX-00THR and TX-0008HR, which are transdermal patch product candidates. The company’s clinical development product is TX-009HR, an oral progesterone and estradiol formulation. It also manufactures and distributes branded and generic prescription prenatal vitamins under the vitaTrue, vitaPearl, vitaMedMD, and BocaGreenMD Prena1 brands. The company sells its prescription prenatal vitamin and hormone therapy drug products to wholesale distributors and retail pharmacy distributors. TherapeuticsMD, Inc. is headquartered in Boca Raton, Florida.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2020/03/30 04:14 |
| End of Day Share Price | 2020/03/27 00:00 |
| Earnings | 2019/12/31 |
| Annual Earnings | 2019/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.